超声定量评估非酒精性脂肪肝病肝脏脂肪变性的研究进展
Research Progress of Quantitative Ultrasound Assessment of Liver Steatosis in Non-alcoholic Fatty Liver Disease
查看参考文献39篇
|
文摘
|
非酒精性脂肪肝病(NAFLD)的发病率不断上升,如不干预可能演变为脂肪性肝炎、肝硬化,甚至发展成肝细胞癌。目前评估NAFLD肝脏脂肪变性严重程度的金标准是肝活检病理,但有创性限制了其成为大面积筛查的手段。近年来磁共振成像相关检查被作为仅次于肝活检的金标准,但仍存在无法大规模应用的缺点。超声具有简便易行、价格低廉、对身体无伤害等优势,有望成为评估NAFLD的重要检查手段。本文总结了受控衰减参数、声衰减成像、超声肝/肾强度比与肝衰减率、背向散射技术定量评估肝脏脂肪变性的研究现状和进展。 |
|
其他语种文摘
|
The incidence of non-alcoholic fatty liver disease (NAFLD) keeps on rise. Without intervention, it may develop to steatohepatitis,cirrhosis,and even hepatocellular carcinoma. Liver biopsy,the gold standard for evaluating the steatosis severity of NAFLD,is invasive and unsuitable for large-scale screening. In recent years,magnetic resonance imaging (MRI) -related examinations have been used as a gold standard only second to liver biopsy,which still have disadvantages in large-scale application. Ultrasound has the advantages of simple operation,low cost,and safety,and may become an important method for accessing NALFD. This review summarizes the current studies about the diagnosis of liver steatosis by quantitative ultrasound assessment,including controlled attenuation parameters,attenuation imaging,ultrasonic liver/kidney intensity ratio and liver attenuation rate,and integrated backscatter. |
|
来源
|
中国医学科学院学报
,2021,43(5):827-832 【核心库】
|
|
DOI
|
10.3881/j.issn.1000-503X.12688
|
|
关键词
|
声衰减成像
;
受控衰减参数
;
非酒精性脂肪肝病
;
肝脂肪变性
;
定量超声
|
|
地址
|
中日友好医院超声医学科, 北京, 100029
|
|
语种
|
中文 |
|
文献类型
|
综述型 |
|
ISSN
|
1000-503X |
|
学科
|
临床医学 |
|
基金
|
中日友好医院引进人才项目
|
|
文献收藏号
|
CSCD:7089737
|
参考文献 共
39
共2页
|
|
1.
中华医学会肝病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病防治指南(2018年更新版).
实用肝脏病杂志,2018,21(3):177-186
|
CSCD被引
65
次
|
|
|
|
|
2.
Younossi Z M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence,incidence,and outcomes.
Hepatology,2016,64(1):73-84
|
CSCD被引
331
次
|
|
|
|
|
3.
Li Z. Prevalence of nonalcoholic fatty liver disease in mainland of China: a meta-analysis of published studies.
J Gastroenterol Hepatol,2014,29(1):42-51
|
CSCD被引
54
次
|
|
|
|
|
4.
Wong R J. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States.
Gastroenterology,2015,148(3):547-555
|
CSCD被引
24
次
|
|
|
|
|
5.
Arulanandan A. Association between quantity of liver fat and cardiovascular risk in patients with nonalcoholic fatty liver disease independent of nonalcoholic steatohepatitis.
Clin Gastroenterol Hepatol,2015,13(8):1513-1520
|
CSCD被引
3
次
|
|
|
|
|
6.
Ajmera V. Magnetic resonance imaging proton density fat fraction associates with progression of fibrosis in patients with nonalcoholic fatty liver disease.
Gastroenterology,2018,155(2):307-310
|
CSCD被引
5
次
|
|
|
|
|
7.
Kleiner D E. Design and validation of a histological scoring system for nonalcoholic fatty liver disease.
Hepatology,2005,41(6):1313-1321
|
CSCD被引
209
次
|
|
|
|
|
8.
Goldstein N S. Fibrosis heterogeneity in nonalcoholic steatohepatitis and hepatitis C virus needle core biopsy specimens.
Am J Clin Pathol,2005,123(3):382-387
|
CSCD被引
3
次
|
|
|
|
|
9.
Kose S. Evaluation of percutaneous liver biopsy complications in patients with chronic viral hepatitis.
Eurasian J Med,2015,47(3):161-164
|
CSCD被引
6
次
|
|
|
|
|
10.
Doycheva I. Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE.
Aliment Pharmacol Ther,2016,43(1):83-95
|
CSCD被引
4
次
|
|
|
|
|
11.
Loomba R. Heritability of hepatic fibrosis and steatosis based on a prospective twin study.
Gastroenterology,2015,149(7):1784-1793
|
CSCD被引
8
次
|
|
|
|
|
12.
Castera L. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease.
Gastroenterology,2019,156(5):1264-1281
|
CSCD被引
30
次
|
|
|
|
|
13.
Park C C. Magnetic resonance elastography vs. transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease.
Gastroenterology,2017,152(3):598-607
|
CSCD被引
16
次
|
|
|
|
|
14.
周永昌.
超声医学. (第6版),2015:780-782
|
CSCD被引
1
次
|
|
|
|
|
15.
梁萍.
超声E成像临床应用指南,2018:13-14
|
CSCD被引
2
次
|
|
|
|
|
16.
Sasso M. Liver steatosis assessed by controlled attenuation parameter (CAP) measured with the XL probe of the FibroScan: a pilot study assessing diagnostic accuracy.
Ultrasound Med Biol,2016,42(1):92-103
|
CSCD被引
2
次
|
|
|
|
|
17.
Ozturk A. Principles of ultrasound elastography.
Abdom Radiol (NY),2018,43(4):773-785
|
CSCD被引
12
次
|
|
|
|
|
18.
Chalasani N. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.
Hepatology,2018,67(1):328-357
|
CSCD被引
194
次
|
|
|
|
|
19.
Naveau S. Controlled attenuation parameter for diagnosing steatosis in bariatric surgery candidates with suspected nonalcoholic fatty liver disease.
Eur J Gastroenterol Hepatol,2017,29(9):1022-1030
|
CSCD被引
1
次
|
|
|
|
|
20.
Eddowes P J. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease.
Gastroenterology,2019,156(6):1717-1730
|
CSCD被引
11
次
|
|
|
|
|
了解气象卫星更多信息，请访问